It was the Dutch Consumers and Markets Authority that handed down its judgment against the Italian company for abusing its dominant position in the market and selling its drug CDCA-Leadiant at an inflated price.
The remedy contains chenodeoxycholic acid, which is used to treat patients with cerebrotendinous xanthomatosis (CTX), a rare inherited metabolic abnormality that causes irreparable damage due to the build-up of fatty acids in different parts of the body.